✦ LIBER ✦

Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: A meta-analysis of randomized controlled trials

✍ Scribed by Andrew E. Thompson; Scott W. Rieder; Janet E. Pope

Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 181 KB
Volume: 63
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.30310

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Anti–tumor necrosis factor α therapy and

Anti–tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis

✍ Sebastian Schneeweiss; Soko Setoguchi; Michael E. Weinblatt; Jeffrey N. Katz; Je 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB

## Abstract ## Objective To assess the association between the initiation of anti–tumor necrosis factor α (anti‐TNFα) therapy and the risk of serious bacterial infections in routine care. ## Methods This was a cohort study of patients with rheumatoid arthritis (RA) in whom specific disease‐modif

Evaluation of the safety of rituximab in

Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: Results from a randomized controlled trial

✍ Maria W. Greenwald; William J. Shergy; Jeffrey L. Kaine; Marianne T. Sweetser; K 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 215 KB 👁 1 views

Treatment with tumor necrosis factor inh

Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis

✍ Lotta Ljung; Julia F. Simard; Lennart Jacobsson; Solbritt Rantapää-Dahlqvist; Jo 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 159 KB 👁 1 views

## Abstract ## Objective Rheumatoid arthritis (RA) is associated with an increased risk of ischemic heart disease, in both early and established RA. Data on the risk of ischemic heart disease in relation to therapy with tumor necrosis factor (TNF) antagonists (anti‐TNF) are conflicting in patients

Atacicept in patients with rheumatoid ar

Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: Results of a phase II, randomized, placebo-controlled, dose-finding trial

✍ M. C. Genovese; N. Kinnman; G. de La Bourdonnaye; C. Pena Rossi; P. P. Tak 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 242 KB 👁 2 views

Single-center series and systematic revi

Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor α therapy: Is there a need for more comprehensive screening procedures?

✍ Nannini, Carlotta ;Cantini, Fabrizio ;Niccoli, Laura ;CassarÀ, Emanuele ;Salvara 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB 👁 1 views

Rates of serious infection, including si

Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register

✍ W. G. Dixon; K. Watson; M. Lunt; K. L. Hyrich; A. J. Silman; D. P. M. Symmons 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 1 views